CIK 0001865494
IOBT IO Biotech, Inc.
Insider trading from SEC Form 4. Last filing Jun 6, 2025.
In brief
IO Biotech, Inc. (IOBT) has 19 SEC Form 4 filings on file from 11 insiders, the latest filed on Jun 6, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at IOBT. The newest: Heidi Hunter (director) bought $21k of stock on May 30, 2025, filed Jun 2, 2025, scored 23 (weak). The largest of the 6 shown: Qasim Iftikhar Ahmad (Chief Medical Officer) bought $27k on Dec 23, 2024, scored 43 (moderate). 4 insiders bought within 14 days of each other around Dec 23, 2024.
1 Form 144 notice of planned sales is on file, the latest filed Feb 9, 2024.
Last 90 days
Signals
Open-market buys and sells at IO Biotech, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Heidi Hunter director buy | $21k 15,000 shares | - | - | |
| 43Moderate | Qasim Iftikhar Ahmad Chief Medical Officer buy | $27k 31,350 shares | - | - | |
| 40Moderate | Devin Whittemore Smith General Counsel buy | $9,720 12,000 shares | +243% | - | |
| 40Moderate | Amy Sullivan Chief Financial Officer buy | $8,483 10,250 shares | +14% | - | |
| 46Moderate | Mai-Britt Zocca Chief Executive Officer buy | $10k 12,500 shares | +33% | - | |
| 25Weak | Brian Burkavage Chief Accounting Officer buy | $10k 10,000 shares | +667% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 9, 2024 | Novo Holdings A/S 10% Stockholder | 658,809 1.00% of outstanding | $1.2M | Feb 9, 2024 | none |
Transactions
Every row filed, 20 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | Christian E Elling director | AGrant or award Stock Option (Right to Buy)derivative | +35,144 | $0.00 | $0 | 35,144 | Jun 6, 2025 |
| Jun 5, 2025 | Kathleen Sereda Glaub director | AGrant or award Stock Option (Right to Buy)derivative | +35,144 | $0.00 | $0 | 35,144 | Jun 6, 2025 |
| Jun 5, 2025 | Peter Hirth director | AGrant or award Stock Option (Right to Buy)derivative | +35,144 | $0.00 | $0 | 35,144 | Jun 6, 2025 |
| Jun 5, 2025 | Heidi Hunter director | AGrant or award Stock Option (Right to Buy)derivative | +35,144 | $0.00 | $0 | 35,144 | Jun 6, 2025 |
| Jun 5, 2025 | David Smith V director | AGrant or award Stock Option (Right to Buy)derivative | +35,144 | $0.00 | $0 | 35,144 | Jun 6, 2025 |
| Jun 5, 2025 | Helen Louise Collins director | AGrant or award Stock Option (Right to Buy)derivative | +35,144 | $0.00 | $0 | 35,144 | Jun 6, 2025 |
| May 30, 2025 | Heidi Hunter director | POpen-market purchase Common Stock | +15,000 | $1.39 | $21k | 15,000 | Jun 2, 2025 |
| Apr 2, 2025 | Amy Sullivan Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Apr 4, 2025 |
| Apr 2, 2025 | Mai-Britt Zocca Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +580,000 | $0.00 | $0 | 580,000 | Apr 4, 2025 |
| Apr 2, 2025 | Devin Whittemore Smith General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Apr 4, 2025 |
| Apr 2, 2025 | Brian Burkavage Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Apr 4, 2025 |
| Apr 2, 2025 | Qasim Iftikhar Ahmad Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Apr 4, 2025 |
| Dec 23, 2024 | Qasim Iftikhar Ahmad Chief Medical Officer | POpen-market purchase Common Stock | +31,350 | $0.85 | $27k | 31,350 | Dec 26, 2024 |
| Dec 23, 2024 | Devin Whittemore Smith General Counsel | POpen-market purchase Common Stock | +12,000 | $0.81 | $9,720 | 16,938 | Dec 23, 2024 |
| Dec 23, 2024 | Amy Sullivan Chief Financial Officer | POpen-market purchase Common Stock | +10,250 | $0.83 | $8,483 | 84,632 | Dec 23, 2024 |
| Dec 23, 2024 | Mai-Britt Zocca Chief Executive Officer | POpen-market purchase Common Stock | +12,500 | $0.81 | $10k | 49,891 | Dec 23, 2024 |
| Mar 15, 2024 | Qasim Iftikhar Ahmad Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Mar 18, 2024 |
| Nov 21, 2023 | Brian Burkavage Chief Accounting Officer | POpen-market purchase Common Stock | +5,000 | $0.99 | $4,950 | 6,500 | Nov 24, 2023 |
| Nov 22, 2023 | Brian Burkavage Chief Accounting Officer | POpen-market purchase Common Stock | +5,000 | $1.04 | $5,175 | 11,500 | Nov 24, 2023 |
| Nov 15, 2023 | Helen Louise Collins director | AGrant or award Stock Option (Right to Buy)derivative | +64,238 | $0.00 | $0 | 64,238 | Nov 17, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Qasim Iftikhar AhmadChief Medical Officer
- Brian BurkavageChief Accounting Officer
- Helen Louise Collinsofficer, director
- Christian E Ellingdirector
- Kathleen Sereda Glaubdirector
- Peter Hirthdirector
- Heidi Hunterdirector
- David Smith Vdirector
- Devin Whittemore SmithGeneral Counsel
- Amy SullivanChief Financial Officer
- Mai-Britt ZoccaChief Executive Officer
Questions about IOBT
Answered from the filings on this page, as of the latest one.
Are insiders buying IOBT?
No. In the last 90 days no insider at IO Biotech, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade IOBT on the open market?
Heidi Hunter (director) bought $21k of IOBT on May 30, 2025 and filed the Form 4 on Jun 2, 2025. InsiderTell scored 23 (weak).
How many insiders file Form 4 at IO Biotech, Inc.?
11 people have filed a Form 4 at IO Biotech, Inc., among them Qasim Iftikhar Ahmad (Chief Medical Officer), Brian Burkavage (Chief Accounting Officer), Helen Louise Collins (officer and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.